Plain-English translation of NCT06307600 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This early-stage trial is testing a new treatment called RD06-03, which involves modifying your own immune cells in a laboratory and then infusing them back into your body to fight leukemia. This medication is designed for patients whose leukemia has either come back after treatment or stopped responding to standard chemotherapy. The trial will track how safe and effective this treatment is over the course of about a year.
Patients with relapsed or refractory acute B-cell leukemia have very limited treatment options and poor outcomes with standard therapies. This trial is exploring whether engineered cell therapy can offer a new hope for patients who have exhausted conventional treatments.
You likely qualify if…
You likely don't qualify if…
You will undergo a procedure called leukapheresis to collect your immune cells, which are then sent to a laboratory to be modified and grown. After the cells are ready, you will receive a single infusion of the modified cells back into your body. You will then be monitored closely for safety and effectiveness over approximately one year, with regular visits to check your blood counts, organ function, and how well the treatment is working.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Anhui Provincial Hospital
Enrollment target
~9 participants
Started
March 2024
Primary completion
March 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
3 Years – 70 Years
Last updated on clinicaltrials.gov in January 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Xiaoyu Zhu, phd
Anhui Provincial Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.